by Edel O'Sullivan, | Oct 22, 2020 | News Release, Press
The Medicines Optimisation Centre and Northern Health and Social Care Trust have today signed a Memorandum of Understanding with the Polish Society of Clinical Pharmacy in order to share learning and drive Pharmacy services throughout Europe.
Memorandum of understanding (MOU or MoU) is an agreement between two or more parties outlined in a formal document. It is not legally binding but signals the willingness of the parties to move forward together.
Northern Ireland is leading the way in pharmacy in Europe and The Medicines Optimisation Innovation Centre is recognised as a driving force in Europe and globally in medicines optimisation, forming strategic partnerships within health
and medicine.
Seamus O’Reilly Medical Director Northern Health and Social Care Trust
“This MOU is a symbol of the level of collaboration between the countries and is a mutual agreement that we will work together to improve medicines safety and medicines optimisation in Europe. It is an opportunity to learn from each other and bring those benefits directly to our patients here in the Northern Health and Social Care Trust
by Edel O'Sullivan, | Oct 16, 2020 | News Release, Press
This event was a first for Northern Ireland and showcased examples from a range of EU partners of how Northern Ireland is co-operating and working cohesively throughout Europe to deliver safer and more effective medicines use.
Medicines safety is a global priority. The Medicines Optimisation Innovation Centre is recognised as a driving force in Europe and globally in medicines optimisation, forming strategic partnerships within health and medicine.
Keynote speakers included Robin Swann MLA Health Minister Northern Ireland, Jennifer Welsh Chief Executive Northern Health and Social Care Trust as well as speakers from Poland, Estonia and the Republic of Ireland discussing how we are all collaborating to improve medicine safety in Europe..
View the event in full below.
EU Regions Event from MOIC on Vimeo.
Available Resources
WHO Patient Safety Challenge
Northern Ireland Pharmacy Response to Covid 19
by Edel O'Sullivan, | Oct 8, 2020 | News Release, Press
Northern Ireland’s Medicines Optimisation Innovation Centre (MOIC) and The Association of the British Pharmaceutical Industry (ABPI) have announced a new partnership to deliver ‘triple win’ benefits to patients, NI Health and Social Care (HSC) and the economy.
Starting with the bold aim of eradicating Hepatitis C in Northern Ireland, the organisations will put in place a new framework to improve patient access to the latest treatments, make more effective use of HSC resources and increase cross-sector medical research.
The partnership agreement signed by MOIC and the ABPI will create a new process whereby HSC will look to industry to help tackle major health challenges which can be addressed by innovative treatments.
Industry will also be able to propose new approaches to unmet health need, which can then be rapidly rolled out across Northern Ireland. One of the first areas the partnership will tackle is Hepatitis C, known as the ‘silent epidemic’ because many sufferers do not know they are infected and therefore do not seek treatment.
Hepatitis C can cause serious liver damage, cancer, and premature death. Incidence is on the rise in Northern Ireland, with cases increasing by 53% in 2019 against the previous ten year average. Untreated, the disease is associated with major costs and productivity losses, estimated for the UK at between £210-£427 million by 2035.
However, a new generation of treatments known as direct acting antivirals can cure the condition, creating a real hope that it can be eradicated as a public health challenge. Maximising access to these treatments in Northern Ireland will is key to delivering that goal and will be an early focus of the new ABPI-MOIC partnership.
Mike Scott, Director of MOIC said:
“We have a long-standing positive relationship with the ABPI and look forward to the benefits that our new partnership will bring. “I’m delighted that tackling Hepatitis C will be one of our first goals. In 2016, the UK signed up to the World Health Organization Global Health Sector Strategy on Viral Hepatitis, which commits participating countries to eliminate the disease as a major public health threat by 2030. We believe our new partnership with the ABPI will help create the conditions for NI to exceed that target.”
Cathy Harrison, Chief Pharmaceutical Officer NI said:
“The Department of Health welcomes the new partnership between MOIC and the ABPI. We believe it will ensure that collaboration is focused on where it can add most value in making innovation as widely available to patients as possible.”
Colette Goldrick, Director ABPI Northern Ireland and NHS Engagement said:
“Cross-sector partnership agreements have already proved effective in GB, and we are delighted to be working with MOIC to bring the same benefits to Northern Ireland.
“Our partnership with Greater Manchester for example has already led to three substantial projects in the fields of Hepatitis C, cancer, and cardiovascular disease, matching NHS needs with industry offers. We want to do the same in Northern Ireland.”
by Edel O'Sullivan, | Sep 24, 2020 | News Release, Press
MOIC complied this report and captured the changes to pharmacy services that were implemented in the Health and Social Care (HSC) service in Northern Ireland during the first wave of the Covid-19 pandemic, between March and May 2020.
It describes the wide range of interventions by pharmacy teams that were necessary to ensure that patients and the public had access to medicines and pharmaceutical care throughout the emergency.
The review makes a number of recommendations for actions needed to prepare for future waves of the pandemic and inform changes needed to support the longer term rebuilding of HSC services.
To view the report in full click here.
by Edel O'Sullivan, | Sep 17, 2020 | News Release, Press, Uncategorized
It’s World Patient Safety Day and it is a day to highlight that patient safety is at the forefront of everything we do.
MOIC is the only dedicated medicines optimisation centre in Europe and we work across Europe to improve medicines use, leading to better patient care. We provide research, project management and offer professional expertise on projects that will improve patient safety through correct medicines use. We engage with partners across Europe and throughout the world on best practice and bring his learning back to Northern Ireland.
Today on World Patient Safety Day, take a look at some of our recent publications, the first examines how medicine optimisation clinics can reduce hospital readmission and the second looks at critical care drug use in ICU during Covid. Both these projects had patient safety as the key driver.
Medicine Optimisation reducing Hospital re-admission
This work looked at how educating patients on their medicine use through dedicated clinics could lead to fewer hospital patients.
https://themoic.hscni.net/medicine-optimisation-reducing-hospital-readmission/
Results
- Readmission rate reduction at 30 days was 9.6%
- Reduction in multiple readmissions over 180-days was 29.1%
Critical Care Drug Requirements
https://themoic.hscni.net/critical-care-drug-requirements-during-covid-19/
The main aim of this work was to develop a process to estimate critical care drug requirements to robustly inform regional procurement planning and preparedness in response to the COVID-19 pandemic. The objectives were to identify critical care drugs required, obtain patient usage data and consider current regional practice to establish the requirement.
by Edel O'Sullivan, | Sep 9, 2020 | News Release, Press
There is a major drive within healthcare to reduce patient readmissions to hospital. MOIC has led research on how a medicines optimisation clinic can change readmission to hospital rates and lead to better patient care.
The research focused on assessing the impact of a post-discharge, pharmacist-led medicines optimisation clinic on readmission within the respiratory and cardiology wards
Adult patients with acute unplanned admission to medical wards were invited to attend clinic to review their medicines and educate patients on proper use of their medicines.
Results
- Readmission rate reduction at 30 days was 9.6%
- Reduction in multiple readmissions over 180-days was 29.1%
A positive impact was also demonstrated in relation to patient beliefs about their medicines and medication adherence.
Anita Hogg Northern Health and Social Trust
“Having delivered the medicines optimisation clinic and supported patients in the safe and effective use of their medicines, I’m delighted that this paper has been published, reinforcing the benefits of a dedicated medicines optimisation clinic to patient care after discharge from hospital”
The post-discharge medicines optimisation clinic was beneficial from a patient care and cost perspective.
Full paper can be found here.
and medicine.